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Intravenous injection of illegal drugs or medications meant for oral administration can cause granulomatous disease of the lung.
This intravascular talcosis results in pulmonary ﬁbrosis and pulmonary hypertension. Nine cases of histologically conﬁrmed
intravascular talcosis were reviewed with speciﬁc attention given to the clinical histories in these patients. Five autopsy cases were
included in this series with detailed investigation in the anatomic features associated with intravascular talcosis and pulmonary
hypertension. All nine patients showed perivascular and/or intravascular deposition of polarizable foreign material in their lungs.
Intravascular talcosis as a result of previous intravenous drug use was not clinically suspected in any patient despite clinically
diagnosed pulmonary hypertension in ﬁve. All patients showed dilatation of the right and left heart, but none had dilatation of
the aortic valve. Congestive heart failure with hepatosplenomegaly was also common. We conclude that intravascular talcosis is an
underdiagnosed cause of pulmonary hypertension in patients with known history of intravenous drug use.
1.Introduction
Pulmonary disease as a result of talc exposure has been
well documented and can have multiple etiologies [1].
Inhalational talc exposure causes talc pneumoconiosis, while
intravenous talc exposure causes intravascular talcosis. The
disease symptoms and gross anatomic ﬁndings in these two
diﬀerent etiologies are essentially identical, and the histology
of these two forms of talc-related lung diseases are also
quitesimilar.Pulmonarydepositionofinsolublemicroscopic
foreign material results in a foreign body giant cell reaction
within the lung parenchyma. Over time and continued
exposure this process results in pulmonary ﬁbrosis, in some
cases extensively. The diﬀerentiating feature between these
two diseases is the location of the foreign material. Inhala-
tionaltalcpneumoconiosisresultsinanalveolardistribution,
and intravascular talcosis leads to a perivascular pattern of
deposition. In acute settings it is also possible to identify
polarizable foreign material within intravascular spaces.
The source of foreign material in intravascular talcosis
is through the intravenous injection of drugs. Illegal street
drugs commonly contain an adulterant to increase the mass,
and this adulterant commonly contains microscopic insol-
uble material. Another common source is the injection of
prescription medications meant for oral use. In these med-
ications which are ground for intravenous injection, there
are ﬁllers and binders added to the medications. In fact
the term intravascular talcosis is a misnomer as talc is only
one of several possible materials used as excipients that also
include methylcellulose and crospovidone [2]. Special stains
have been shown to have the ability to diﬀerentiate the com-
position of intravascular foreign material in diagnostically
diﬃcult situations [3].
With the intravenous injection of foreign material, the
lungs represent the ﬁrst capillary bed to serve as a ﬁlter to
remove this material. Due to the size of much of this material
itusuallybecomeslodgedinthepulmonaryvasculature.This
results in acute small embolization of vessels. Over time the
foreign material is deposited in perivascular tissues, and for-
eign body giant cell reaction occurs with associated ﬁbrosis.
This ﬁbrosis of the lung parenchyma in turn results in the
development of pulmonary hypertension in some patients.2 Pulmonary Medicine
Intravascular talcosis as a cause of pulmonary hypertension
has been well documented since the early description of this
disease in the 1960s although the term intravascular talcosis
has not been commonly used in the past [4, 5].
The diagnosis of intravascular talcosis has important
social and medical treatment implications but is not com-
monly suspected in many patients even in the presence of
known intravenous drug abuse [6]. Here we present nine
cases of intravascular talcosis on biopsy and autopsy cases
that were not clinically suspected. We give a detailed review
of the patient histories. In ﬁve autopsy cases we also include
detailed analysis of the pulmonary and cardiac disease re-
lating to intravascular talcosis. The goal of this study is to
increaseawarenessofintravasculartalcosisasacauseforpul-
monary hypertension and to present clinical and anatomic
features that can suggest the diagnosis.
2.MaterialsandMethods
Cases of intravascular talcosis were identiﬁed through a nat-
ural language search for “talc” in our electronic laboratory
information system over an eleven-year-period spanning 1/
2000–12/2010. Surgical specimens and autopsy cases were
included in the search. Final diagnoses were reviewed to
select cases of intravascular talcosis, and slides were reviewed
by the authors to conﬁrm the diagnosis. Cases were excluded
if slides or blocks were not available for review or the
diagnosis was not conﬁrmed. In autopsy cases, all slides were
pulled and examined for the presence of polarizable foreign
material in association with histocytic inﬁltration. The
clinical histories of patients with conﬁrmed intravascular
talcosis were abstracted for relevant clinical data. This study
was approved by the UPMC Institutional Review Board (IRB
no. PRO11020060).
2.1. Deﬁnition of Normal Metrics. Left ventricular hyper-
trophy was deﬁned as wall thickness greater than 1.5cm
and right ventricular hypertrophy as wall thickness greater
than 0.5cm. Mitral valve dilation was deﬁned as valve
circumference greater than 9.9cm in males and 9.1cm in
females, aortic valve dilation as valve circumference greater
than 8.5cm in males and 7.9cm in females, tricuspid valve
dilation as valve circumference greater than 11.8cm in males
and 11.1cm in females, and pulmonic valve dilation as valve
circumference greater than 7.5cm in males and 7.4cm in
females [7]. Cardiomegaly was determined as a function
of sex and body mass using the report by Kitzman et al.
[7]. Splenomegaly was deﬁned as spleen weight greater than
245 grams in males and greater than 190 grams in females.
Hepatomegaly was deﬁned as liver weight greater than 2000
grams in males and greater than 1800 grams in females.
Increased lung weight was deﬁned as combined lung weight
greater than 1050 grams.
3. Results
3.1. Clinical Features of Intravascular Talcosis. A total of nine
cases of intravascular talcosis are included in this study—ﬁve
autopsy cases and four lung biopsy cases. Demographics for
these patients are summarized in Table 1.T h ea v e r a g ea g e
for all patients was 44 years. Three cases were diagnosed in
patients with admitted drug use that was not recent, and
these patients had a higher average age at 56 years. There was
a predominance of males with only one female in the nine
patients.
The clinical histories of the patients were variable and are
brieﬂy described herein. Case 1 had a history of intravenous
drug use and IgA nephropathy and was admitted for dyspnea
and chest pain. Case 2 had a history of intravenous drug
use and coronary artery disease and presented with acute
chest pain. Case 3 had a history of remote intravenous drug
use and history of stroke and was found unresponsive at his
skilled nursing facility. Case 4 had a history of remote intra-
venous drug use, chronic obstructive pulmonary disease,
and multiple pneumothoraces and was admitted for new
pneumothorax and possible lung transplant evaluation. Case
5 had a history of intravenous drug use, chronic obstructive
pulmonarydisease,andchronicbackpainrequiringmultiple
surgeries and presented with a new episode of severe back
pain. Case 6 had a history of remote intravenous drug use
andrightlungtransplantationfortalcosisandpresentedwith
increased work of breathing. Case 7 presented in the trauma
suite with multiple traumatic penetrating chest injuries; a
pneumonectomy was performed, but the patient did not
survive. No history is available for this patient. Case 8
had a history of deteriorating lung function due to severe
emphysema and presented for double lung transplantation.
Case9hadahistoryofmultiplespinesurgeriesandpresented
with an enlarged periaortic lymph node and pulmonary
inﬁltrate. While the majority of patients (6 of 8) with
histologically conﬁrmed intravascular talcosis had admitted
intravenous drug abuse, two denied intravenous drug use.
Other common clinical features were hepatitis C seroposi-
tivity (7 of 8 tested) and tobacco use (6 of 8 with history).
Pulmonary hypertension was clinically diagnosed in ﬁve
of the nine patients based on clinical features, cardiac
catheterization, and echocardiography. Four patients had
cardiac catheterization data available for review with all hav-
ingelevatedpeakpulmonaryarterypressureswithanaverage
of43mmHg(range37–50mmHg).Enddiastolicpulmonary
artery pressures were increased in only two patients (average
15.25mmHg, range 4–22mmHg). Mean pulmonary artery
pressures reported were elevated in two patients (aver-
age 25.25mmHg, range 20–32mmHg). Echocardiography
(either transthoracic or transesophageal) studies were per-
formed in six patients. Two patients had completely normal
studies. Four patients had abnormal ﬁndings: mild right
atrial dilatation (2), moderate-to-severe right ventricular
dilatation (3), moderate pulmonary artery dilatation (2),
moderate pulmonary hypertension (3; peak pulmonary sys-
tolic pressures 52–70mmHg), moderate left atrial dilatation
(2), mild left ventricular hypertrophy (1), severe left ventric-
ular hypertrophy (1), and mildly decreased left ventricular
ejection fraction (3).
Five patients had chest computed tomography per-
formed prior to pathological examination. Three showed
emphysematous changes, one showed centrilobular and in-
terstitial nodules, and one showed bibasilar atelectasis versusPulmonary Medicine 3
Table 1: Demographics for cases of talc granulomatosis.
Case Specimen Sex Age (years) Admitted
IVDU Hep C Tobacco
smoking
Pulmonary
symptoms/diagnoses
1A u t o p s y M 3 7 Y e s N e g a t i v e n o Dyspnea
Pulmonary HTN
2 Autopsy M 40 Yes Positive yes
3 Autopsy M 62 Yes, remote Positive no
4 Autopsy M 55 Yes, remote Positive yes
IPF
Pulmonary HTN
Recurrent
pneumothoraces
5 Autopsy F 44 Yes Positive yes COPD
6 Transbronchial biopsy M 51 Yes, remote Positive yes
Dyspnea
Pulmonary HTN s/p R
lung transplant for talc
exposure∗
7 Pneumonectomy due
to trauma M 2 0 N AN AN A
8
Double lung
transplant native
lungs
M5 3N o P o s i t i v e y e s Dyspnea
Mild pulmonary HTN
9 Wedge resection M 31 No NA yes
Dyspnea
Pleuritic chest pain
Pulmonary HTN
∗Initially diagnosed with talc pneumoconiosis.
Abbreviations: HTN: hypertension, IPF: idiopathic pulmonary ﬁbrosis, COPD: chronic obstructive pulmonary disease, s/p: status post, NA: not available.
pneumonia. In one patient with severe panlobular emphy-
sema, diﬀuse ﬁbrosis was also evident.
Pulmonary function testing was performed in four pa-
tients, and the following parameters were noted to be
abnormal: forced vital capacity (FVC) (4 patients; 26–72%
of predicted), forced expiratory volume in 1 second (FEV1)
(4; 22–65% of predicted), diﬀusing capacity of the lung for
carbon monoxide (DLCO) (4 patients; 1 with 62% of pre-
dicted and 3 others that were unattainable due to low lung
volumes), and vital capacity (VC) (4 patients; 36 and 73% of
predicted in 2 patients, and unattainable in 2 patients).
Regarding relevant medical comorbidities, seven out of
eight patients with known baseline status had a past medica
l history signiﬁcant for hypertension that required medical
management. Three patients had a history of chronic renal
insuﬃciency (one of whom had IgA nephropathy and even-
tually required hemodialysis), and one patient developed
acute renal failure prior to death.
At the time of initial pathological diagnosis, no patients
wereclinicallysuspectedofhavingintravasculartalcosis.One
patient had previously been diagnosed with inhalational talc
pneumoconiosis at an outside institution based on biopsy.
Following this diagnosis the patient had a single-sided lung
transplant, and a later biopsy at our institution of the
nontransplanted native lung was diagnostic of intravascular
talcosis. This patient had a history of remote intravenous
drug use. Another patient experienced multiple bilateral
spontaneous pneumothoraces and was diagnosed with idio-
pathic pulmonary ﬁbrosis; however, histological examina-
tion of the patient’s lungs at autopsy demonstrated intravas-
cular talcosis as a cause for his pulmonary ﬁbrosis.
3.2. Histologic Features of Intravascular Talcosis. The low
power microscopic appearance in histologic sections of the
lungs varied from focal areas of foreign body reaction and
ﬁbrosis to cases with extensive areas of ﬁbrosis (Figure 1).
The common ﬁnding in all cases was the diagnostic feature
of a perivascular localization of foreign material deposition
and ﬁbrosis (Figure 2). In cases with extensive ﬁbrosis the
perivasculardepositioncouldstillbeseeninareaswithresid-
ual alveolated lung. The morphology of the foreign material
itself varied with some showing more plate-like material and
others more needle-like material (Figures 3(a) and 3(b)).
Occasional asteroid bodies were found in some cases
(Figure 3(c)). The histologic sections from autopsy cases and
two of the four surgical pathology specimens showed some
classical features associated with pulmonary hypertension
[8]. Many medium caliber arteries showed hypertrophy
of the muscular walls and larger arteries, when seen on
sections, showed intimal proliferation similar to that seen in
atherosclerosis. Many of the smaller caliber vessels failed to
show these changes, and no plexiform vascular lesions were
seen.
3.3. Anatomic Findings in Intravascular Talcosis Seen at
Autopsy. Anatomic ﬁndings in the ﬁve patients having au-
topsy can be seen in Table 2. Causes of death included
cardiac failure with pulmonary edema, cardiac arrhythmia
secondary to pulmonary thromboembolus, multisystem
organ failure secondary to sepsis, pulmonary ﬁbrosis, and
cardiopulmonary decompensation from pulmonary hyper-
tension. All ﬁve patients had increased lung weights with an
average of 1,894 grams. Cardiomegaly was present in three4 Pulmonary Medicine
(a)
(b)
Figure 1: Low-power magniﬁcation of two cases of intravascular
talcosis. The degree of ﬁbrosis ranged from focal ﬁbrosis in perivas-
c u l a ra r e a s( a )t od i ﬀuse areas of ﬁbrosis (b). Foreign material can
be seen within areas of ﬁbrosis associated with a foreign body giant
cell reaction. Polarization of the material is evident in (b).
Table 2: Anatomic features of intravascular talcosis.
Average organ weights (grams) [range]
Lungs (1894) 1490–2490
Heart (600) 350–1030
Liver (2421) 1300–4110
Spleen (437) 80–860
Average heart valve circumference (cm)
Mitral (10.9) 10.5–11.5
Aortic (7.2) 6.5–8
Tricuspid (13.5) 12–15.5
Pulmonic (8.5) 7–10
of ﬁve patients with an average heart weight of 600.4 grams.
All ﬁve patients showed dilation of both right and left
heart. The mitral and tricuspid valves were dilated in all
5 patients, average circumference of 10.9cm and 13.5cm,
respectively. The pulmonic valve was dilated in 4 of 5 with an
average circumference of 8.5cm. None of the 5 patients had
dilation of the aortic valve, average circumference 7.2cm.
Hepatomegaly was present in three of ﬁve and splenomegaly
(a)
(b)
Figure 2: Higher magniﬁcation view of perivascular deposition of
foreign material with foreign body giant cell reaction and ﬁbrosis
(a). The foreign material is highlighted under polarization (b).
in four of ﬁve patients. The presence of polarizable foreign
material was also present in extrapulmonary tissues in each
of the ﬁve patients—bone marrow (3), lymph nodes (2),
kidneys (2), spleen (2), liver (2), myocardium (2), thyroid
(1),venousthrombus(1),andrightventricularthrombus(1)
(Figure 4). One patient that is not deceased had prior biop-
sies of the liver and retina which showed similar polarizable
foreign material. In each of the extrapulmonary tissues, the
foreign material was intra-or perivascular, showed smaller
particles than in the lungs, and lacked signiﬁcant giant cell
reaction. In one patient with transbronchial lung biopsy,
previous biopsies of the retina and liver were reported to
show polarizable foreign material. Four patients had evi-
dence of moderate-to-severe coronary artery atherosclerosis,
and three had histologic evidence of subendocardial and/or
myometrial ischemia.
4. Discussion
The ﬁnding of perivascular or intravascular polarizable
foreign material in the lungs is essentially diagnostic of
intravascular talcosis due to intravenous injection of ille-
gal drugs. The most important diﬀerential to establish isPulmonary Medicine 5
(a) (b) (c)
Figure 3: The foreign material deposits of intravascular talcosis have varying morphologies. Some cases showed more plate-like polarizable
material (a) while other cases showed more needle-like morphology (b). Asteroid bodies are a common ﬁnding in intravascular talcosis (c).
(a) (b)
(c) (d)
Figure 4: Systemic sites of foreign material are an important feature seen in intravascular talcosis. This material is smaller than seen in the
lungs and only rarely incites a foreign body giant cell reaction. Representative ﬁgures show deposition in lymph node (a), liver (b), bone
marrow (c), and heart (d).
between intravascular talcosis and talc pneumoconiosis due
to inhalation of microscopic dust. The diﬀerentiation of
these two etiologies in foreign material associated granu-
lomatous lung disease can be challenging as perivascular
location in some ways includes the entire lung parenchyma.
In this paper we searched for and selected cases of intra-
vascular talcosis based on the histological location of the
polarizable foreign material in perivascular or intravascular
locations. Our ﬁndings show that none of the nine patients
included in this study were clinically suspected of having
intravascular talcosis due to intravenous drug abuse. This is
despite the fact that ﬁve had clinically diagnosed pulmonary
hypertension and six had admitted history of intravenous
drug abuse.
While the eﬀects of intravascularly injected talc had an
adverse impact on these patients’ hemodynamic proﬁles as6 Pulmonary Medicine
described in the current study, it is interesting to note that
many of the histologic specimens demonstrated talc that was
found to be distributed in the perivascular area and not
intravascularly. While a deﬁnitive answer to explain this is
elusive, one plausible hypothesis is that small talc particles
are extravasated from the vascular space over time by the
hydrostatic pressure within the vessels. The fact that a
majority of patients in the current analysis had systemic
hypertensionwouldalsofacilitatethismovement.Withtime,
macrophages (and resulting giant cells) may also contribute
to the movement of this foreign material farther from the
intravascular space. Ultimately, ﬁbrosis of this milieu of
talc, immune cells, and perivascular stroma around the
pulmonary vessels would, in addition to any remaining in-
travascular talc, contribute to the increased pulmonary
artery pressures.
Fibrosis and occlusion of small vessels within the lungs
of these patients due to the intravascular and/or perivascular
deposition of insoluble foreign material is the most probable
cause of pulmonary hypertension in light of the clinical
history and anatomic ﬁndings; however, contributions from
other aspects of the patients’ comorbidities, such as emphy-
sema and ﬁbrosis of other etiologies, cannot be completely
excluded.Theanatomicﬁndingsintheﬁvepatientsundergo-
ingautopsywerealllikelyrelatedtothepulmonaryhyperten-
sion in these patients. While the phenomenon of pulmonary
hypertension in patients with intravenous drug use is well
documented this is the ﬁrst report to our knowledge to care-
fully examine the changes to the heart related to the disease.
In the cases presented here all patients had dilatation of the
left and right heart as determined by enlarged valve circum-
ference. Cardiomegaly was also common being seen in three
of ﬁve patients. Despite this ﬁnding none showed dilatation
of the aortic valve. The reason for this is not known. Features
of left sided congestive heart failure with hepatomegaly and
splenomegaly were also common.
The additional evidence to support the diagnosis in these
patients was the common ﬁnding of ﬁne birefringent mate-
rial in systemic locations in these patients. This feature has
been previously reported in patient with intravascular talco-
sis [9]. This ﬁnding should suggest the diagnosis of intravas-
cular talcosis rather than talc pneumoconiosis in patients
with pulmonary granulomas as inhalation of talc and related
material should not result in systemic deposition. The
smaller size of the material in the systemic sites compared to
the lung parenchyma suggests that this material was small
enough to escape the pulmonary capillary bed.
Our analysis yielded ﬁndings from non-invasive testing
which may increase suspicion for this disease in high risk
individuals. Right-sided cardiac dilatation and pulmonary
artery dilatation/hypertension were each found in at least
half of patients that underwent echocardiography. Addition-
ally, all patients (4/4) who underwent pulmonary function
testing had decreased FVC and FEV1, along with either
decreased or unattainable (due to low lung volumes) VC and
DLCO.
In the current study, hypertension requiring medical
treatment was present in 7 out of 8 patients that were as-
sessed. Only three patients had chronic kidney insuﬃciency
(an additional patient had acute renal failure prior to
death), and one of these required hemodialysis. Additionally,
autopsy ﬁndings demonstrated either moderate-to-severe
atherosclerotic disease or cardiac ischemia. These relevant
cardiac and renal co-morbidities may have contributed
to the observed cardiac ﬁndings, and while intravascular
talcosis and its hemodynamic impacts may have exacerbated
theseconditions,theirdeﬁnitiverelationshiptointravascular
talcosis is unknown.
Intravascular talcosis as a result of intravenous injection
of drugs is not an uncommon ﬁnding but is not universally
seen in all intravenous drug users, and the ﬁnding of pul-
monary hypertension has been previously reported in these
patients [5]. The current study demonstrates that intravas-
cular talcosis is an underrecognized cause of pulmonary
hypertension despite the combination of pulmonary hyper-
tension and a history of intravenous drug use in many of
ourpatients.Patientswithriskfactorsandﬁndingsidentiﬁed
herein may beneﬁt from further clinical evaluation for
intravascular talcosis.
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